|
|
Causes analysis and precautions of missed and mistaken diagnosis of atypical pancreatic cancer |
LIU Xin LIU Wanli▲ KAN Minqiang LIU Yi YU Yang |
Department of Internal Medicine, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Jiangsu Province, Nanjing 210014, China |
|
|
Abstract According to statistics, the incidence of pancreatic cancer is increasing year by year. Because of lacking obvious early symptoms and effective early diagnosis deficiency, the rate of missed and mistaken diagnosis is high. By analyzing the cause of missed and mistaken diagnosis of eleven pancreatic cancer cases, this article investigates the effective measures of precautions of missed and mistaken diagnosis of pancreatic cancer, such as diagnosing and differential diagnosing simultaneously, improving the diagnosis and treatment skill of iconography doctors, dynamic observing multiple tumor markers and so on, for reference of relevant scholars.
|
|
|
|
|
[1] 李兆申,余志良,周国中,等.胰腺癌误诊因素分析[J].解放军医学杂志,2002,27(4):304-306.
[2] 邱万勇.血清CA19-9水平在胰腺癌预后判断中的应用进展[J].中国医药导报,2014,11(14):151-153.
[3] 吕翼,魏若征,吴河水.胰腺癌的早期诊断[J].临床急诊杂志,2018,19(3):149-151.
[4] 孟宪镛.实用消化病诊疗学[M].3版.上海:世界图书出版公司,2001:563-566.
[5] 张薇,唐喜玉,肖茂林,等.35例胰腺癌误诊分析[J].皖南医学院学报,2010,29(3):223-224.
[6] 周永昌,郭万学.超声医学[M].4版.北京:科学技术文献出版社,2002:1012.
[7] 李朝霞,彭玉兰.胰腺癌超声漏误诊30例原因分析[J].临床超声医学杂志,2008,10(10):714-715.
[8] 梁秀梅.胰腺癌与反复发作性胰腺炎的临床及CT鉴别诊断[J].重庆医学,2011,40(28):2833-2835.
[9] 杨红,钱家鸣,郭涛.胰腺癌300例临床特点分析[J].基础医学与临床,2007,27(7):815-818.
[10] 李伟.胰腺癌12例误诊分析[J].临床误诊误治,2007,20(4):43.
[11] 杨红,钱家鸣,郭涛.胰腺癌300例诊断分析[J].临床误诊误治,2006,19(4):32-33.
[12] 赵书萍.胰腺癌误诊26例原因分析[J].中国误诊学杂志,2007,7(13):3057.
[13] 刘锁贵,武建英.胰腺癌四例早期误漏诊的教训[J].临床误诊误治,2008,21(11):60-61.
[14] 崔云涛.胰腺癌的早期CT与MRI诊断[J].影像研究与医学应用,2017,1(17):117-118.
[15] 徐宏斌.血清CA19-9、CA242、CEA联合检测对胰腺癌的诊断价值[J].齐齐哈尔医学院学报,2017,38(16):1876-1877.
[16] 韩忠学,巩静,郑艳.血清糖类抗原与癌抗原对胰腺癌诊断价值[J].临床军医杂志,2016,44(10):1052-1054.
[17] 金鑫.联合检测肿瘤抗原199、肿瘤抗原242及D-二聚体对胰腺癌早期诊断的意义[J].中国医药导报,2015, 12(19):136-139.
[18] 李学彦,郭晓钟,李宏宇,等.肿瘤标志物检测在胰腺癌诊断和预后评估中的价值研究[J].中国实用内科杂志,2014,34(5):499-503.
[19] 邵银剑.CA19-9 在胰腺癌放疗中的预后价值[J].中国医药导报,2010,7(10):209-210.
[20] 曹圆圆,张坚.糖类抗原CA50和CA242在101例胰腺癌诊断中的临床应用评价[J].肿瘤学杂志,2016,22(5):430-432.
[21] Ni XG,Bai XF,Mao YL,et al. The clinical value of serum CEA,A19-9,and CA242 in the diagnosis and prognosis of pancreatic cancer [J]. Eur J Surg Oncol,2005,31(2):164-169. |
|
|
|